* Champions Oncology Inc reported quarterly adjusted earnings of 5 cents per share for the quarter ended October 31, higher than the same quarter last year, when the company reported EPS of -15 cents. The lone analyst forecast for the quarter was for earnings of one cent per share.
* Revenue rose 16.6% to $13.49 million from a year ago; analysts expected $13.05 million.
* The company reported quarterly net income of $728 thousand.
* Champions Oncology Inc shares had risen by 7.0% this quarter and lost 7.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 133.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Champions Oncology Inc is $6.00 This summary was machine generated from LSEG data December 11 at 09:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Oct. 31 2024 0.01 0.05 Beat
Jul. 31 2024 -0.03 0.11 Beat
Apr. 30 2024 -0.16 0.01 Beat
Jan. 31 2024 -0.06 -0.16 Missed
Comments